ASTRAZENECA PHARMA INDIA LIMITED

For the Indian arm of the British pharmaceutical firm AstraZeneca, the revenue generation was Rs 24 crore during FY 20-21 in the biopharma space, showing a growth of 12 per cent in comparison to the revenue generation of Rs 21 crore in the previous year. During FY 20-21, the company received marketing authorisation from the government for Dapagliflozin (Forxiga) for the treatment of patients with heart failure with reduced ejection fraction; Benralizumab (Fasenra) for asthma patients; and anti-diabetic drug dapagliflozin for the treatment of patients of chronic kidney disease (CKD) up to stage III. On the global front, AstraZeneca was majorly involved in COVID-19 vaccine development.